Effects of Green Banana BIOmass Consumption in Patients With Pre-diabetes and Diabetes MELlitus (The BIOMEL Study)
Launched by FEDERAL UNIVERSITY OF SÃO PAULO · Jul 24, 2017
Trial Information
Current as of June 22, 2025
Unknown status
Keywords
ClinConnect Summary
INTRODUCTION Cardiovascular Disease and Diabetes In Brazil, chronic non-communicable diseases (NCDs) were the cause of 72% of deaths and reached 63% in the world in 2008, with large numbers of premature deaths. Cardiovascular disease (31.3%), Diabetes Mellitus (DM) (5.2%), cancer (16.3%) and respiratory disease (5.8%) are the main causes of NCDs, leading to loss of quality of life, causing economic impacts that lead to increased poverty. These factors can be reversed through broad interventions and cost-effective health promotion. (Schmidt et al, 2011;. Malta et.al., 2011).
Currently, it i...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • having signed the written informed consent
- • males and females aging 18-85 years
- • glycated hemoglobin \>= 6.5% for diabetic patients
- • glycated hemoglobin between 5.7% and 6.4% for pre-diabetic patients
- • on stable dose of anti-diabetic drugs and without antecipation of dosage changes during study protocol
- Exclusion Criteria:
- • use of insulin
- • those who need change in dose or addition of medication for diabetes
- • any malignancies, except basocelular carcinoma
- • heart failure with NYHA class III or IV
- • renal failure (GFR\< 30 mL/min) or under dialysis therapy
- • AIDS
- • uncontrolled hypothyroidism (TSH \> 10 uUI/mL)
- • active liver disease
- • severe psychiatric disorders
- • any other disease that in the opinion of the investigator could interfere in the results
About Federal University Of São Paulo
The Federal University of São Paulo (Universidade Federal de São Paulo - UNIFESP) is a prestigious institution dedicated to advancing education, research, and healthcare in Brazil. Renowned for its commitment to innovation and excellence, UNIFESP plays a pivotal role in clinical research, focusing on a multidisciplinary approach to improve health outcomes. The university fosters collaboration among researchers, healthcare professionals, and community stakeholders, ensuring that clinical trials conducted under its auspices adhere to rigorous ethical standards and contribute valuable insights to the medical field. With a rich history of academic achievement and a strong emphasis on translational research, UNIFESP is a key player in the development of new therapies and medical interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sao Paulo, Sp, Brazil
Patients applied
Trial Officials
Maria C Izar, M.D., Ph.D.
Principal Investigator
Federal University of Sao Paulp
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials